7Health Ventures raises $70m.

7Health Ventures will invest in 12 companies, ranging from seed-stage to more advanced stages and will focus on companies that address significant medical needs, such as heart disease, obesity and neurological diseases.

By MATTHEW KRIEGER
September 18, 2007 07:53

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

7Health Ventures,, a new venture capital fund founded by Dr. Dalia Megiddo, announced on Monday that it has raised $70 million for investing in medical technologies. 7Health Ventures will invest in 12 companies, ranging from seed-stage to more advanced stages and will focus on companies that address significant medical needs, such as heart disease, obesity and neurological diseases. The fund will collaborate with leading international medical device companies as well as leading international academic research centers. The fund's investors are headed by Ms. Ruth Wertheimer.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS